Plant mitochondrial genome engineering: technology development and application to study fundamental aspects of mitochondrial gene expression

PlaMitEng aims to enable genetic engineering of plant mitochondrial genomes through novel editing and transformation technologies, unlocking new research and biotechnology opportunities.

Subsidie
€ 2.500.000
2024

Projectdetails

Introduction

PlaMitEng has the highly ambitious overall objective to make the mitochondrial genome of seed plants amenable to genetic engineering.

Project Overview

The project consists of two complementary work packages (WPs).

WP1: TALEN-GDM

In WP1, TALEN-GDM, a technology for plant mitochondrial genome editing recently developed by us will be used to systematically study plant mitochondrial gene expression in vivo.

  • The focus will be on:
    1. Translation initiation
    2. Translational regulation in mitochondria

The mechanisms of which are currently completely unknown.

WP2: Direct Genetic Transformation

In WP2, PlaMitEng will develop a technology for direct genetic transformation of the plant mitochondrial genome.

  • The mitochondrial genome is the only genome of the plant cell that, due to the lack of a mitochondrion-specific selection system, is not amenable to transformation and has remained recalcitrant to the insertion and expression of transgenes.

Taking advantage of:

  1. Our recent construction of a mitochondrion-specific selectable marker gene
  2. The generation of a dedicated recipient line for mitochondrial transformation
  3. The design of a new transformation strategy (referred to as multivectorial transformation)

This will enable the large-scale testing of expression elements for their suitability to drive the expression of mitochondrial transgenes in vivo.

Future Opportunities

PlaMitEng will pursue the development of a robust technology for transformation of the plant mitochondrial genome. The possibility to express transgenes from plant mitochondrial genomes will open up entirely new opportunities in both basic and applied research, and pave the way to harnessing the enormous potential of mitochondrial biotechnology and synthetic biology.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.500.000
Totale projectbegroting€ 2.500.000

Tijdlijn

Startdatum1-7-2024
Einddatum30-6-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EVpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Advanced...

Mitochondrial gene eXpression

This project aims to elucidate the mechanisms regulating mitochondrial gene expression by investigating transcript interactomes and translation dynamics in both organello and in vivo contexts.

€ 1.913.968
ERC Proof of...

In planta jet injection: Efficient genetic engineering of resilient crops

The project aims to develop affordable, high-throughput devices for efficient genome editing in crops to enhance yield and climate resilience, addressing global food security challenges by 2100.

€ 150.000
ERC Starting...

Developing technologies to engineer plant genomes at the megabase scale

The OMEGA project aims to identify essential plant genes and develop Megabase-scale genome editing tools to enhance genomics and synthetic biology applications in plants.

€ 1.496.250
ERC Starting...

Structural studies of the human mitochondrial RNA life cycle

MitoRNA aims to elucidate the molecular mechanisms of mitochondrial RNA metabolism and gene expression coupling using integrated structural biology to advance mitochondrial biology understanding.

€ 1.499.754
ERC Proof of...

Biophysical Genetic Design Automation Technology

The PLATE project aims to create a modular software suite that integrates advanced biophysical models for accurate design of synthetic biology circuits, addressing context-dependency challenges for reliable applications.

€ 150.000

Vergelijkbare projecten uit andere regelingen

EIC Transition

PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal cells and T cells

This project aims to develop an automated high-throughput PEN photoporation system for safely and efficiently genetically modifying T cells and MSCs for cancer therapy commercialization.

€ 2.497.711
EIC Accelerator

Next generation gene writing platform to cure genetic and oncological diseases

Integra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases.

€ 2.496.375
EIC Transition

3P-Tec - Three-parent breeding technology for plants of the future

The project aims to develop a revolutionary three-parent breeding technology (3P-Tec) to create climate-resilient crops, enhancing yields and accelerating the commercialization of improved seed varieties.

€ 2.498.828
Mkb-innovati...

Genetisch gemodificeerde micro-organismen op een bio-based dieet

EV Biotech onderzoekt de haalbaarheid van genetisch gemodificeerde micro-organismen die zetmeel kunnen afbreken voor duurzame biomolecuulproductie, ter vervanging van dure glucose.

€ 20.000
EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

€ 2.988.377